Monopar Therapeutics (MNPR) Total Non-Current Liabilities (2020 - 2025)
Quarterly results put Total Non-Current Liabilities at $2.9 million for Q4 2025, down 44.99% from a year ago — trailing twelve months through Dec 2025 was $2.9 million (down 44.99% YoY), and the annual figure for FY2025 was $2.9 million, down 44.99%.
Monopar Therapeutics has reported Total Non-Current Liabilities over the past 3 years, most recently at $2.9 million for Q4 2025.
- Total Non-Current Liabilities reached $2.9 million in Q4 2025 per MNPR's latest filing, up from $2.6 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $5.3 million in Q4 2024 and bottomed at $1.5 million in Q1 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 11.03 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | 42,980.09 |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 95.20 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | 110.28 Mn |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 5.87 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 7.32 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Monopar Therapeutics | 466.82 Mn | 466.82 Mn | - | 2.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.89 Mn |
| Sep 30, 2025 | 2.64 Mn |
| Jun 30, 2025 | 1.66 Mn |
| Mar 31, 2025 | 1.49 Mn |
| Dec 31, 2024 | 5.25 Mn |
| Sep 30, 2020 | 54,628.00 |
| Jun 30, 2020 | 75,021.00 |